Hey there, bargain hunter.
The weight loss drug story was supposed to be getting crowded by now. More competition, more pills, more pressure on pricing. And sure — there is real noise in the sector.
But the fundamentals underneath it are moving in a direction most people have not fully priced.
Here Is Where Things Stand
Eli Lilly delivered 56% revenue growth in Q1 2026 to $19.8 billion. Mounjaro and Zepbound together generated roughly $12.8 billion in that quarter alone. Full-year 2026 guidance was raised to $82-85 billion. The FDA approved Foundayo — Lilly’s oral GLP-1 pill — on April 1, 2026. And the Phase 3 TRIUMPH-1 trial for retatrutide, Lilly’s next-generation obesity drug, showed patients on the 12 mg dose losing an average of 70.3 pounds — 28.3% of body weight — over 80 weeks. A prespecified 104-week extension showed average loss of 85 pounds, or 30.3% of body weight.
Those are results that, as one analyst put it, are often associated with bariatric surgery.
More than 45% of TRIUMPH-1 participants lost at least 30% of body weight. On the 12 mg dose. In a drug that still awaits regulatory submission.
The Oral Pill Changes the Market Size
This is where it gets interesting. Until recently, GLP-1 therapy meant weekly injections. A lot of people with obesity who could benefit simply did not want that. Novo Nordisk was first to market with an oral GLP-1 pill and reported total weekly prescriptions of ~50,000 shortly after launch. Then Lilly got FDA approval for Foundayo on April 1.
What makes Foundayo different is the absence of food and water restrictions. You can take it any time of day. That matters for adherence. Per Lilly’s Q1 2026 earnings call materials, 80%+ of early Foundayo prescriptions came from patients new to the incretin class. A drug pulling mostly new patients into the category expands the market rather than cannibalizing existing injectable volume.
Starting July 1, 2026, CMS will begin the Medicare GLP-1 Bridge, which provides eligible Medicare beneficiaries access to certain GLP-1 medications for $50 per month through December 31, 2027. That is not a rounding error.
The Risk the Market Is Currently Pricing
A survey released in mid-June showed a meaningful share of large employers reconsidering whether they will keep covering GLP-1 drugs for weight management in 2027. Health insurer Cigna already dropped GLP-1 coverage for weight loss for its own employees starting July 1. Lilly shares dipped on that news and remain under some pressure, closing around $1,129 in mid-June.
That is a real risk. Employer coverage is a big piece of the commercial insurance market, and if that source of volume softens, near-term volume growth could disappoint even as the underlying demand story remains intact.
The counterweight: Medicare coverage is opening at almost the same moment employer coverage may tighten. CVS Caremark — one of the largest pharmacy benefit managers in the country — reversed a previous decision and will restore Zepbound to its standard commercial formularies on October 1, with Foundayo no longer blocked as “new-to-market” starting June 1 (where plans elect coverage). The net picture is not obviously bearish.
The Valuation Tension
LLY stock closed around $1,129 in mid-June 2026, just below the 52-week high of approximately $1,166. The stock has returned about 50% over the trailing twelve months.
One model puts a reasonable 2028 price target around $1,373 per share — about 22% upside from the mid-June price — assuming a 27.5x exit PE multiple on compounding earnings. That multiple would actually represent some compression from where Lilly has historically traded. The bull case does not require multiple expansion. It requires earnings growth to continue — which, given the Medicare tailwind, oral pill adoption, and retatrutide coming to market, is not an unreasonable assumption.
The Broader Ecosystem Play
Smaller names are worth tracking. Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are both advancing GLP-1-based therapies that could challenge the incumbents at the margin. Neither is a Lilly competitor yet, but both represent the kind of optionality that can move fast on positive trial data.
Novo Nordisk (NVO) is the other half of this trade. NVO has had a rougher year than Lilly, trading at a meaningful discount after its 2025 reset. If the total addressable market in obesity pharmacotherapy is as large as the data suggests, there may be room for both companies to win even as Lilly pulls ahead on market share.
Slight tangent: Zealand Pharma’s survodutide just stumbled on tolerability/discontinuation data, reminding everyone that not every challenger drug is going to make it. The obesity space rewards execution, not just ambition. Lilly has both right now.
Cheap Investor Scorecard
- LLY Q1 2026 revenue: $19.8B, up 56% year over year
- Mounjaro and Zepbound combined Q1 revenue: approximately $12.8B
- 2026 full-year revenue guidance: $82-85B
- Foundayo FDA approval: April 1, 2026; 80%+ of early Rx from new-to-class incretin patients
- TRIUMPH-1 top-line (retatrutide 12 mg): 28.3% average weight loss at 80 weeks; 30.3% at 104 weeks
- Medicare GLP-1 Bridge access: begins July 1, 2026; $50/month for eligible beneficiaries (through Dec. 31, 2027)
- CVS Caremark: restoring Zepbound to standard commercial formularies October 1, 2026; Foundayo no longer blocked as “new-to-market” starting June 1, 2026 (where plans elect coverage)
- LLY trailing 12-month total shareholder return: approximately 50%
- Employer coverage risk: some employers reconsidering 2027 GLP-1 coverage for weight management
The obesity market is not a bubble. It is a chronic disease category with a penetration rate that is still in the single digits relative to the total patient population who could benefit. Oral pills lower the barrier. Medicare coverage widens the funnel. And retatrutide, if it reaches market, could make everything before it look like a first-generation product.
Lilly is not cheap in the traditional sense. But for what you are actually buying — a drug franchise that is still expanding its addressable market, with a pipeline several layers deep — the valuation may be more reasonable than the headline stock price suggests.
The employer coverage story is the variable to watch in the next two quarters. If it softens without the Medicare offset absorbing volume, the stock gets messier before it gets cleaner. If Medicare proves to be the demand catalyst Lilly’s CEO thinks it will be, the current price could look like the entry point people wish they had taken.